- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02296242
Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes
Phase 1/2 Dose-Escalation, Safety, Clinical Activity, Pharmacokinetic and Pharmacodynamic Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes
Study Overview
Status
Intervention / Treatment
Detailed Description
The study is being performed to assess the safety and tolerability of BVD-523 given orally, twice daily for 21-day cycles.
Part 1 of the study will establish dose limiting toxicities (DLT), maximum tolerated dose (MTD), and the recommended Phase 2 dose (RP2D).
In Part 2 of the study, additional patients with particular tumor types and/or cancers harboring specific genetic mutations will be recruited for treatment at the Recommended Phase 2 Dose (RP2D). Patients may also be assessed pharmacodynamic measures in healthy or malignant tissues, using biomarker assays for phosphorylation, cytotoxic or cytostatic measures.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90024
- UCLA Medical Center
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Winship Cancer Institute of Emory University
-
-
New York
-
Buffalo, New York, United States, 14263
- Roswell Park Cancer Institute
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Perelman Center for Advanced Medicine
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Have either of the following diagnoses:
- Morphologically confirmed acute myeloid leukemia (AML), except acute promyelocytic leukemia (APL), including leukemia secondary to prior therapy or antecedent hematologic disorder (e.g., MDS or myeloproliferative disorders), who have failed to achieve CR or who have relapsed after prior therapy and are not candidates for potentially curative therapy
- Intermediate-2 or High-grade risk MDS (including chronic myelomonocytic leukemia (CMML))
- Have received at least one prior therapy. Patients who are over age 65 and have not received therapy for AML are also eligible, if they are not candidates for induction chemotherapy
- ECOG performance status of 0 to 2
- Predicted life expectancy of ≥ 3 months
- Adequate liver, renal and cardiac function
For Group 1 in Part 2 of the Study ONLY:
• Positive for RAS mutation at a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory prior to study entry
Exclusion Criteria:
- Concomitant malignancies except carcinoma in situ, basal or squamous cell skin carcinoma; low grade prostate cancer treated with prostatectomy more than 10 years ago; early stage melanoma treated with complete surgical excision more than 5 years ago; carcinoma in situ of cervix treated with cone procedure more than 8 years ago
- Gastrointestinal condition which could impair absorption of study medication
- Uncontrolled or severe intercurrent medical condition
- Patients with rapidly increasing peripheral blood blast counts
- Known uncontrolled central nervous system involvement
- Any cancer-directed therapy within 28 days or 5 half-lives, whichever is shorter
- Any concurrent or prior use of an investigational drug (including MEK inhibitors) within previous 28 days or 5 half-lives, whichever is shorter
- Received chemotherapy regimens with delayed toxicity within the last four weeks (six weeks for prior nitrosourea or mitomycin C). Received chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity within the last two weeks.
- Ongoing anticoagulant therapy that cannot be held if necessary to permit bone marrow sampling.
- Major surgery within 4 weeks prior to first dose
- Pregnant or breast-feeding women
- Any evidence of serious active infections
- Any important medical illness or abnormal laboratory finding that would increase the risk of participating in this study
- A history or current evidence/risk of retinal vein occlusion or central serous retinopathy
- Concurrent therapy with drugs known to be strong inhibitors of CYP1A2, CYP2D6, and CYP3A4, or strong inducers of CYP3A4
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BVD-523
|
Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients With Dose Limiting Toxicities
Time Frame: In the first 21 days of treatment
|
DLT defined using CTCAE v.4.03.
All toxicities were considered to be related to BVD523 if not definitively explained by underlying disease, intercurrent illness, or con meds.
|
In the first 21 days of treatment
|
Steady-state Plasma Concentration of BVD-523 and Selected Metabolites Over 12 Hours
Time Frame: Samples will be collected on or about Day 22 of the protocol
|
The PK population consisted of patients who received at least one dose of BVD-523 and had evaluable PK data in plasma.
|
Samples will be collected on or about Day 22 of the protocol
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Evidence of Cancer Response in Bone Marrow Biopsies
Time Frame: Until patient discontinuation; ~24 months on average
|
Assessments were made via bone marrow biopsies using the International Working Group 2003 and 2006 criteria for AML or MDS, respectively.
Bone marrow assessments (aspiration or biopsy, cytogenetics) were collected prior to therapy on Day 1 and Day 22, every 2 cycles thereafter, as well as at the final study visit if discontinuation was not due to disease progression.
Some patients were unable to have bone marrow assessments taken at any or all of the time points.
Shown is best response across all time points.
Less than partial remission/response (<PR), partial remission/response (PR), complete remission/response with incomplete platelet recovery (CRp), or complete remission/response (CR).
|
Until patient discontinuation; ~24 months on average
|
Duration of Disease Control in Patients That Respond
Time Frame: Until patient discontinuation; ~24 months on average
|
Assessments were made via bone marrow biopsies using the International Working Group 2003 and 2006 criteria for AML or MDS, respectively.
Progression-free survival (PFS) and duration of response (DOR) of AML or MDS patients was assessed in patients treated with BVD-523 that achieved complete remission/response (CR) or complete remission/response with incomplete platelet recovery (CRp).
<PR = less than partial remission/response.
Shown is the duration (number of days) of CR or CRp response for the 2 patients in part 2 that obtained this level of response.
|
Until patient discontinuation; ~24 months on average
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacodynamic Results of Inhibition (%) of Molecular Target (ERK Pathway) Assessed by Blood and Tissue Analyses.
Time Frame: Patients will be evaluated at baseline and on or about Day 22 of the protocol
|
Multiple biomarkers intended to demonstrate inhibition of the molecular target, and mechanism of action were investigated from blood and/or bone marrow aspirate samples.
Phosphorylation of ERK enzyme substrate proteins (e.g.
RSK1 and RSK2 genes) were measured.
Additional biomarkers, including PBMCs and/or DNA sequence analysis, were identified and measured as appropriate.
Measurements were by ELISA.
The pharmacodynamics (PD) population was defined as all patients who received at least one dose of study drug and had sufficient, valid PD samples to estimate key parameters for at least one of the days of sampling.
|
Patients will be evaluated at baseline and on or about Day 22 of the protocol
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BVD-523-02 (Other Identifier: BioMed Valley Discoveries, Inc.)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myelodysplastic Syndrome
-
Brian JonasNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.CompletedPreviously Treated Myelodysplastic Syndrome | Myelodysplastic Syndrome | Therapy-Related Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic SyndromeUnited States
-
Thomas Jefferson UniversityAbbVieRecruitingMyelodysplastic Syndrome | Recurrent Myelodysplastic Syndrome | Refractory Myelodysplastic SyndromeUnited States
-
Uma BorateRecruitingTherapy-Related Myelodysplastic Syndrome | Secondary Myelodysplastic SyndromeUnited States
-
University Hospital, BrestRecruitingMyelodysplastic Syndromes | Myelodysplastic Syndrome With Isolated Del(5Q) | Myelodysplastic Syndrome With Del(5Q)France
-
Cyclacel Pharmaceuticals, Inc.SuspendedLeukemia | Myelodysplastic Syndrome(MDS)United States
-
I-Mab Biopharma Co. Ltd.Recruiting
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI)RecruitingMyelodysplastic Syndromes (MDS)United States, Israel
-
AbbVieCelgene; Genentech, Inc.CompletedMyelodysplastic Syndromes (MDS)United States, Australia, Germany
-
AbbVieGenentech, Inc.Active, not recruitingMyelodysplastic Syndromes (MDS)United States, Australia, Canada, France, Germany, Italy, United Kingdom
-
The First Affiliated Hospital with Nanjing Medical...UnknownMyelodysplastic Syndromes (MDS)China
Clinical Trials on BVD-523
-
BioMed Valley Discoveries, IncCompleted
-
BioMed Valley Discoveries, IncCompletedAdvanced Solid TumorsUnited States
-
Dana-Farber Cancer InstituteBioMed Valley Discoveries, IncActive, not recruiting
-
xCuresCancer CommonsAvailableExpanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered MalignanciesMelanoma | Head and Neck Cancer | Glioblastoma | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Bowel Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Bladder Cancer | Thyroid Cancer | ERK Mutation | MAPK Gene Mutation | KRAS Activating... and other conditionsUnited States
-
BioMed Valley Discoveries, IncTerminatedAdvanced Solid Tumor | MAP2K1 Gene Mutation | BRAF Gene Mutation | MEK Mutation | BRAF Gene Alteration | MEK Alteration | MAP2K1 Gene Alteration | MAP2K2 Gene Mutation | MAP2K2 Gene AlterationUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditionsUnited States, Puerto Rico
-
M.D. Anderson Cancer CenterEli Lilly and Company; BioMed Valley Discoveries, IncRecruiting
-
UNC Lineberger Comprehensive Cancer CenterPfizer; BioMed Valley Discoveries, IncRecruitingMelanoma | Pancreatic Cancer | Tumor, SolidUnited States
-
University of UtahBioMed Valley Discoveries, IncCompletedGastrointestinal NeoplasmsUnited States
-
BioMed Valley Discoveries, IncRecruitingGastrointestinal Cancer | Tumor, SolidUnited States